Twenty-seven dogs were treated with either oclacitinib, a Janus Kinase (JAK) inhibitor that primarily targets JAK1-dependent signaling pathways (n = 17), or lokivetmab, a caninized monoclonal antibody that targets interleukin-31, a cytokine that induces pruritus in dogs (n = 10). The gene discussed is JAK1; the disease is Pruritus.